



**Q4 and Fiscal Year 2007
Earnings Call Presentation
February 12, 2008**


Forward Looking Statements and GAAP Reconciliation

This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 relating to future events or our future performance, including statements with respect to our expectations regarding, but not limited to the financial forecast for 2008, the launch of new products, and maintenance of a leadership position in core markets. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in those forward-looking statements. These risks may include, but are not limited to the risk associated with our ability to commercialize new products and identify new markets for our technology; our ability to manage our growth; competition and pricing pressure and risks related to our intellectual property. These risks and other factors are summarized under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2006, filed with the Securities and Exchange Commission on June 15, 2007. These factors are updated from time to time through the filing of reports and registration statements with the Securities and Exchange Commission. We do not assume any obligation to update the forward-looking information contained in this press release.

In addition, this presentation includes no-GAAP financial measures. Syneron provides reconciliation information at the end of this presentation and on its investor relations page at www.syneron.com.

Annual Revenue 2005-2007 (\$ million)


\$ Millions



Full year sales totaled \$141 million, representing 21% y-o-y growth

Quarterly Revenue 2005-2007 (\$ million)


\$ Millions




Q4 Highlights:

- Record quarterly sales of \$38 million

Geographic Segments 2007




2007 Total



Q4 2007

Revenue Guidance 2008

\$ Millions



P&L Summary: Q4 2007 and Full Year 2007

	Q4 2007		2007 Full Year	
Revenue	\$38 million		\$141 million	
Gross Margin	79%		81%	
Stock-based compensation	\$0.4 million		\$7.8 million	
Impairment charge	\$5.8 million		\$5.8 million	
	GAAP	Non-GAAP	GAAP	Non-GAAP
Operating Income	\$8.8m	\$9.2m	\$31.0m	\$38.8m
Operating Margin	23%	24%	22%	22%
Net Income (millions)	\$4.4m	\$10.6m	\$31.2m	\$44.8m
Earnings Per Share (diluted)	\$0.16	\$0.38	\$1.12	\$1.61

Other Financial Highlights Q4 2007

- Cash position (including investments in long-term marketable securities) of \$203.8 million
- Net cash from operating activities for Q4 of \$21.4 million
- DSO declines to 105 days from 122 days in Q3 07 (monthly average balance basis)
- Shareholders' equity \$230.8 million
- No debt


Share Repurchase Program

- Program started Nov. 15, 2007
- Board of Directors authorized purchase of shares up to \$50 million
- 466,000 million shares repurchased at cost of \$7.2 million
- Average share price \$15.45

Syneron 2008: New Product Launches

- Targeted R&D investment focused on high growth segments
 - Body shaping
 - Skin Rejuvenation
- Flexibility in usage of device and business model to suit doctor's practice
- Diversifying revenue stream for Syneron
 - Recurring revenue from disposables and new business model

A Multi-faceted Product Strategy for the Body Shaping Market



Syneron's Laser-assisted Liposuction Product



- Surgical platform for future applications

- Optimized for laser assisted liposuction

- Recurring revenue for Syneron

- Low risk business model offers flexible options to physicians

Matrix RF Flexibility

YSGG

Nd-YAG




CO₂

Er-Glass

Er-YAG

- Matrix RF can emulate broad range of ablative lasers
- Matrix RF applicator can be used on all Syneron “eLine” platforms: eLight, eLaser, eMax
- Single use disposable tip

Matrix RF Flexibility



- **Matrix RF can emulate broad range of ablative lasers**
- **Matrix RF applicator can be used on all Syneron “eLine” platforms: eLight, eLaser, eMax**
- **Single use disposable tip**

2007 Highlights

- Syneron continues to capture market share
- Signing of global exclusive agreement with Procter & Gamble to develop and supply home use devices to improve skin appearance
- Successful launch of VelaShape and Matrix IR
- Successful implementation of unique customer care and practice support solutions (e.g.ReFirme campaign)
- Smooth management transition

2008 Goals

- Fuel organic growth innovation in R&D
- Further diversify the revenue base towards a service-oriented business model with recurring revenue streams
- Continue to improve operating leverage through additional optimization of marketing and sales expenses
- Expand and solidify the home use initiative

Q&A